美托洛尔用于风湿性心脏病慢性心力衰竭中的疗效评价

Efficacy Evaluation of Metoprolol in Chronic Heart Failure with Rheumatic Heart Disease

目的探讨分析美托洛尔用于治疗风湿性心脏病慢性心力衰竭的临床疗效。方法在该院方便选取2017年4月—2018年4月期间收治的风湿性心脏病慢性心力衰竭患者共96例,采用信封法将其平均分为观察组与对照组。其中对照组服用常规治疗药物(稳心颗粒药物),观察组服用常规药物同时联合美托洛尔治疗。对比两组患者服药6个月后心率(HR)、左室舒张末内径(LVEDD)、左室收缩末内径(LVESD)、左室射血分数(LVEF)以及不良反应发生率。结果观察组头痛、胸痛和恶心等不良反应发生率4.17%低于对照组16.67%,差异有统计学意义(χ^2=4.0186,P=0.0450<0.05)。观察组HR(79.52±4.83)次/min、LVEDD(53.47±4.93)mm、LVESD(50.38±5.05)mm低于对照组(81.45±4.37)次/min、(56.26±4.52)mm、(52.66±5.27)mm,观察组LVEF(51.39±5.74)%高于对照组(48.32±5.23)%。组间差异有统计学意义(t=2.0528、2.5924、2.1641、2.7390,P=0.0429、0.0111、0.0330、0.0074<0.05)。结论在常规用药基础上,服用美托洛尔对于风湿性心脏病慢性心力衰竭患者的临床疗效显著,降低其不良反应发生率,具有临床价值。

Objective To investigate the clinical efficacy of metoprolol in the treatment of chronic heart failure in rheumatic heart disease.Methods Convenient selected a total of 96 patients with chronic heart failure in rheumatic heart disease admitted between April 2017 and April 2018 were enrolled in our hospital.The patients were divided into observation group and control group by envelope method.The control group received conventional treatment(Metacenter granules),and the observation group received conventional drugs combined with metoprolol of heart rate(HR),left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD),left ventricular ejection fraction(LVEF),and adverse reaction rate were compared between the two groups.Results The incidence of adverse reactions such as headache,chest pain and nausea in the observation group was 4.17%lower than that in the control group 16.67%,the difference was statistically significant(χ^2=4.018 6,P=0.045 0<0.05).The observation group HR(79.52±4.83)times/min,LVEDD(53.47±4.93)mm,LVESD(50.38±5.05)mm was lower than the control group(81.45±4.37)times/min,(56.26±4.52)mm,(52.66±5.27)mm,the observation group LVEF(51.39±5.74)%was higher than the control group(48.32±5.23)%.The difference between the groups was significant,and there was statistical significance(t=2.052 8,2.592 4,2.164 1,2.739 0,P=0.042 9,0.011 1,0.033 0,0.007 4<0.05).Conclusion On the basis of conventional medication,the clinical efficacy of metoprolol in patients with chronic heart failure of rheumatic heart disease is significant,reducing the incidence of adverse reactions,and has clinical value.